Jefferson Health, affiliated with the university, is already home of the Sidney Kimmel Cancer Center. During the 90-day period, each party will perform due diligence to evaluate whether a deal would benefit cancer patients while also serving each organization’s strategic interests.
“The negotiation period will allow us to better understand how partnering could improve lives for patients throughout Philadelphia and far beyond,” said Stephen Klasko, MD, president of Thomas Jefferson University and CEO of Jefferson Health. “Just imagine the potential of combining the stellar researchers and clinicians of Fox Chase Cancer Center with the outstanding experts at Sidney Kimmel Cancer Center at Jefferson. This could save — and change — lives forever.”
As part of the potential agreement, Thomas Jefferson University and Temple University would also enter into a long-term oncology-related academic affiliation.
More articles on transactions and valuations:
Health M&A to rebound, increase 7% in 2019
UPMC plans 2nd hospital in Italy
KentuckyOne gets new bid for Jewish Hospital, other assets
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
